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Abstract: Chronic prostatitis is a disease with an unknown etiology that affects a large number of 
men. The optimal management for category III chronic prostatitis/chronic pelvic pain syndrome 
(CP/CPPS) is unknown. The recent years have seen a signiﬁ  cant increase in research efforts 
to understand, classify and treat CP/CPPS. Standard treatment usually consists of prolonged 
courses of antibiotics, even though well-designed clinical trials have failed to demonstrate their 
efﬁ  cacy. Recent treatment strategies with some evidence of efﬁ  cacy include: alpha-blockers, 
anti-inﬂ  ammatory agents, hormonal manipulation, phytotherapy (quercetin, bee pollen), phys-
iotherapy and chronic pain therapy. A stepwise, multimodal approach can be successful for the 
majority of patients who present with this difﬁ  cult condition.
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Introduction
Chronic prostatitis remains somewhat of an enigma in Urology. Ever since its 
description in 1968 (Meares and Stamey 1968) and initial attempt at classiﬁ  cation 
10 years later (Drach et al 1978), this condition has been long on hypotheses and short 
on hard data. The last 10 years have, however, seen signiﬁ  cant growth in research on 
prostatitis, resulting in better evidenced-based therapies. This review will focus on the 
latest development on the treatment strategies developed for the treatment of category 
III/chronic pelvic pain syndrome (CPPS) of the NIH classiﬁ  cation (Krieger, Nyberg, 
and Nickel 1999). Category III prostatitis (previously referred to as nonbacterial pros-
tatitis or prostatodynia) is deﬁ  ned by the persistent symptoms of pelvic and genital 
pain and urinary symptoms without evidence for urinary tract infection.
General supportive measures
Although efﬁ  cacy has not been demonstrated in clinical trials, men with CP/CPPS are 
frequently suggested to avoid spicy food, caffeine and alcohol, together with sitz baths. 
The issue of ejaculation is controversial, as some men report exacerbation of symptoms 
(Shoskes et al 2004) whereas other report reduction (Yavascaoglu et al 1999) with 
regular ejaculation. Stress has also been convincingly associated with CPPS. Indeed, 
in a well designed study, Ullrich et al (Ullrich et al 2005) reported greater perceived 
stress during the 6 months after the healthcare visit was associated with greater pain 
intensity and disability at 12 months. Based on those ﬁ  ndings, stress reduction is 
frequently advocated. Importantly, stress reduction can assist in reducing the disability 
and response to pain. Furthermore, men with CP/CPPS are more likely to suffer from 
neurologic and psychiatric conditions then control patients (Pontari et al 2005). 
Antimicrobials
At some point in the natural course of the disease, it is possible that bacterial infection 
is implicated in the etiology of CP/CPPS. Even though uropathogenic bacteria are Therapeutics and Clinical Risk Management 2007:3(4) 508
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cultured from a minority of patients with CP/CPPS, antimi-
crobial therapy is the most commonly prescribed treatment 
(McNaughton et al 2000). Importantly, there is no difference 
in culture results of urine and prostatic ﬂ  uid between men 
with CPPS and asymptomatic controls.
The prostatic tissue is best penetrated by lipophillic drugs 
that have high pKa. In this group, we ﬁ  nd the quinolones, the 
macrolides and sulfa drugs. Based on their pharmacokinetic 
proﬁ  le, the quinolones are the drug of choice for patients with 
CP/CPPS. From a microbiological stand point, their broad 
spectrum (Chlamydia, mycoplasma and both gram positive 
and gram negative bacteria) also cover most uropathogens. 
In non-placebo controlled studies, ciproﬂ  oxacin, levaquin and 
lomeﬂ  oxacin have all proved clinically effective for patients 
with category II prostatitis (chronic bacterial)  (Naber, Busch, 
and Focht 2000; Naber and European Lomeﬂ  oxacin Prostatitis 
Study Group, 2002; Wagenlehner et al 2005). Unfortunately, 
neither levaquin nor ciproﬂ  oxacin were found more effective 
than placebo in a randomized controlled trial in men with CPPS 
(Nickel et al 2003a; Alexander et al 2004). Macrolides such as 
azithromycin or clarithromycin also penetrate the prostate well 
(Giannopoulos et al 2001). These drugs have been reportedly 
used with some success in men with CP/CPPS (Skerk et al 
2002, 2003, 2004), but never in the context of a randomized 
controlled trial. In light with the above-mentioned results, a 
critical analysis of the therapies for use in CP/CPPS, among 
which antibiotics, can be found in the Cochrane Database of 
Systematic Reviews, and the available data so far does not 
support use of antibiotics in CP/CPPS (McNaughton, Mac, 
and Wilt 2001). 
The observed beneﬁ  cial effect of antibiotics in some trials 
could be explained by a placebo effect or through a mechanism 
of action of the compounds not related to their antimicrobial 
activity. Antibiotics such as quinolones and macrolides have 
potent anti-inﬂ  ammatory effects independent of their anti-
microbial effects. It is also unclear if bacteria in the prostate 
proliferate in a environment protected by bioﬁ  lms, as this may 
affect the choice of antibiotics (Arakawa et al 1999). 
Despite these controversies, antimicrobials remain the 
most common treatment used in patients with CP/CPPS. 
While it appears that some patients with CP/CPPS show 
clinical improvement with antimicrobials, prolonged use 
without a documented infection or symptomatic improve-
ment is unwarranted.
Prostate massage and ejaculation
Before the availability of broad-sprectum antimicrobials, 
prostatic massage was the mainstay of treatment for patients 
with prostatitis (O’Conor 1936). Mechanistically, prostate 
massage could help drain occluded prostatic duct and increase 
penetration of the gland by antimicrobial agents (Hennenfent 
and Feliciano 1998). It could also disrupt bacterial bioﬁ  lms 
or massage a neuromuscular trigger point along the pelvic 
side wall. In a non-controlled study, prostate massage 2–3 
times per week for 4–6 weeks with concurrent antibiotic 
treatment had some clinical beneﬁ  t in patients with CP/
CPPS (Nickel et al 1999). Frequent ejaculation achieves 
similar results (Yavascaoglu, Oktay, Simsek et al 1999). It 
has also been demonstrated that 40% of CP/CPPS patients 
treated with antibiotics and prostatic massage had lasting 
clinical improvement, especially if there was large volume 
of clumpy expressed prostatic secretions (EPS) at the ﬁ  rst 
visit or if prostate cultures remained positive despite adequate 
antibiotics (Shoskes and Zeitlin 1999).
Alpha-blockers
CP/CPPS patients also frequently present with lower urinary 
tract symptoms (LUTS) of both obstructive and irritative 
nature. Furthermore, some of these patients will present 
with urodynamic evidence of bladder outlet obstruction 
(Barbalias, Meares Jr, and Sant 1983; Murnaghan and 
Millard 1984; Kaplan, Te, and Jacobs 1994; Mayo, Ross, 
and Krieger 1998; Liao, Shi, and Liang 1999). A subset of 
these patients will also have ultrasonographic evidence of 
bladder neck hypertrophy (Di Trapani et al 1988) with an 
accompanying obstructive pattern on uroﬂ  owmetry (Ghobish 
2002). Such dysfunctional voiding is, however, probably 
not the predominant factor for the majority of men suffer-
ing from CP/CPPS (Murnaghan and Millard 1984; Mayo, 
Ross, and Krieger 1998) and the use of urodynamic testing 
in patients with CP/CPPS is not widely accepted (Stroh-
maier and Bichler 2000). Alpha-blockers can also have a 
direct effect on pain. It has been demonstrated that prostatic 
inﬂ  ammation leads to substance P-mediated changes in the 
pain perception regions of the spinal cord and that these 
changes are blocked by tamsulosin (Ishigooka et al 2002). 
Importantly, the presence of urinary symptoms does not 
correlate with improvement in pain in CPPS patients who 
take alpha blockers.
A well designed study with alfuzosin was performed 
in patients with CP/CPPS and demonstrated a small, but 
statistically signiﬁ  cant improvement in the NIH-CPSI score 
(Mehik et al 2003). The effect was only apparent after several 
months of treatment and disappeared when the treatment was 
stopped. Results with tamsulosin are mixed, with one study 
demonstrating a signiﬁ  cant effect (Nickel et al 2004b) and an-Therapeutics and Clinical Risk Management 2007:3(4) 509
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other one no effect (Alexander, Propert, Schaeffer et al 2004) 
when comparing against placebo. The latter negative study 
used a shorter treatment duration and included men who may 
have failed alpha blocker therapy in the past. Terazosin was 
also found to be superior to placebo in another study (Cheah 
et al 2004). Until larger deﬁ  nitive trials are completed, it ap-
pears reasonable to attempt treatment of CP/CPPS patients 
with 3–6 months of an alpha-blocker.
Anti-inﬂ  ammatory
There is growing evidence that inflammation plays a 
signiﬁ  cant role in CP/CPPS. Indeed, elevated levels of 
inﬂ  ammatory cytokines (Alexander et al 1998; Miller et al 
2002; Nadler et al 2000; Paulis et al 2003), low level of the 
anti-inﬂ  ammatory cytokine interleukin-10 (Miller, Fischer, 
Goralnick et al 2002),  reactive oxygen species (Pasqualotto 
et al 2000) and endorphin or prostaglandins (Shahed and 
Shoskes 2001) have all been associated with the diagnosis or 
symptom severity of patients with CP/CPPS when compared 
to healthy controls. It may be possible that an initial bacterial 
infection triggers a dysregulated inﬂ  ammatory reaction.
Nonsteroidal anti-inﬂ  ammatory drugs have long been 
used in CP. In a non-controlled study, it has been shown that 
ketoprofen suppository or oral nimesulide had some efﬁ  cacy 
in CP/CPPS patients (Canale et al 1993). There is a well 
designed, blinded placebo-controlled study of an anti-inﬂ  am-
matory agent in CP/CPPS patients in which a small effect was 
observed (Nickel et al 2003b). Unfortunately, the drug used, 
rofecoxib, has been voluntary withdrawn by its manufacturer. 
Corticosteroids also have potent anti-inﬂ  ammatory activity, 
and in a small, non-controlled study, prednisolone was effec-
tive in relieving symptoms of patients with CP/CPPS (Bates 
and Talbot 2000). One must carefully weigh the beneﬁ  ts and 
risk of using steroids to treat patients with CP/CPPS and their 
multiple side effects. Some phytotherapeutic agents, to be 
discussed later, may act by preventing inﬂ  ammation.
Hormonal manipulation
The inﬂ  uence of androgen on the development of the prostate 
is well known, together with the effects of androgen depri-
vation. In a non-controlled study of men with CP/CPPS, 
ﬁ  nasteride use led to signiﬁ  cant and durable improvement in 
symptoms (Kaplan, Volpe, and Te 2004). In a randomized, 
placebo controlled study of ﬁ  nasteride used in combination 
with other therapies, there was some symptom improve-
ment seen (Nickel et al 2004a). The effect was small, 
however, and the authors did not recommend monotherapy 
with ﬁ  nasteride unless a signiﬁ  cant component of BPH was 
present. Phytotherapeutic agents, to be discussed later, may 
act through similar mechanisms.
Surgery and minimally invasive therapy
Unless a speciﬁ  c indication is encountered during a work-up 
of patients with CP/CPPS, surgery does not have an impor-
tant role in its treatment. In the 1980’s, it was popular to try 
a “radical” TURP with mixed results (Barnes, Hadley, and 
O’Donoghue 1982) and it is no longer advocated for patients 
with CP/CPPS. With the introduction of minimally invasive 
therapy, a surgical option was again explored. Transurethral 
needle ablation (TUNA) of the prostate was shown to be of 
beneﬁ  t in men with CP/CPPS in open-label studies (Lee et al 
2002; Chiang and Chiang 2004). However, a sham controlled 
study could not demonstrate any efficacy of TUNA in 
men with CP/CPPS (Leskinen et al 2002a). Another mini-
mally invasive approach is transurethral microwave therapy 
(TUMT). It has been studied in men with CP/CPPS, and 
found to be effective in non-controlled studies (Servadio and 
Leib 1991; Michielsen et al 1995; Mene et al 1997; Cho et al 
2000; Leskinen et al 2002b; Kastner et al 2004). The main 
issue is whether the high temperatures used in BPH therapy 
are necessary for CP/CPPS and whether prostatic necrosis 
may lead to an increase in the inﬂ  ammatory component of 
the condition. Sham controlled studies are required before 
these therapies can be recommended for routine use.
Alternative medicine
With an apparent dissatisfaction with ‘standard’ medical 
approach to the treatment of CP/CPPS, a large number of 
patients are seeking relief outside of traditional approaches. 
For instance, acupuncture has been reported to be effective 
in patients with CP/CPPS (Ge, Meng, and Xu 1988; Chen 
et al 1995; Chen and Nickel 2004; ). However, none of those 
studies are adequately controlled. 
Phytotherapy is another alternative to allopathic medica-
tions. Herbal-based therapies are prevalent and popular in uro-
logic disease, more so in prostatic disorders, with compelling 
evidence (Shoskes 2002). Examples include: Chinese herbs 
(Jia et al 2001; Xu, Zhang, and Ding 2003; Han et al 2004;), 
green tea extracts (Lee et al 2005), quecertin (Shoskes et al 
1999; Katske et al 2001), saw palmetto (Kaplan, Volpe, and 
Te 2004) and bee pollen (Buck, Rees, and Ebeling 1989; Buck 
et al 1990; Rugendorff et al 1993; Chen et al 2002; Elist 2006). 
Unfortunately, not all studies are adequately controlled. 
Extracts of bee pollen are thought to be effective in 
prostatic conditions from their presumed anti-inﬂ  ammatory 
and anti-androgen effects (Buck, Rees, and Ebeling 1989; Therapeutics and Clinical Risk Management 2007:3(4) 510
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Buck, Cox, Rees, et al 1990). In an open-label study, 
90 patients received one tablet of Cernilton N three times 
a day for 6 months. Excluding patients with complicating 
anatomic factors (urethral stricture, bladder neck stenosis or 
prostatic calculi) who had a minimal response to the treatment 
(1 or 18 patients saw improvement), 36% of the remaining 
patients were cured of their symptoms while another 42% saw 
their symptoms improved (Rugendorff, Weidner, Ebeling, 
et al 1993). In a double-blind randomized study with a differ-
ent pollent extract (Prostat/Poltit), Elist et al reported signiﬁ  -
cant clinical improvement when comparing with the placebo 
group (Elist 2006). Saw palmetto, probably the most com-
monly used phytochemical in prostatic conditions, is believed 
to act, in part, through an anti-androgen/anti-inﬂ  ammatory 
mechanism has been tested in a open-label study in patients 
with CP/CPPS (Kaplan, Volpe, and Te 2004). However, it 
was not found to be more effective than placebo. 
Quercetin, a polyphenolic bioﬂ  avonoid, is commonly 
found in red wine, green tea and onions (Hollman et al 
1997; Hollman and Katan 1998). It is a biologically active 
compound with well demonstrated anti-inﬂ  ammatory prop-
erties (Guardia et al 2001) and can, for instance, inhibit the 
production of inﬂ  ammatory cytokines presumably implicated 
in the etiology of CP/CPPS such as tumor necrosis factor and 
interleukin-8 (Sato et al 1997). In a prospective, randomized 
double-blind placebo controlled study using the NIH-CPSI as 
end-point, 500 mg of Quercetin was administered twice a day 
for 4 weeks to CP/CPPS patients (Shoskes, Zeitlin, Shahed, 
et al 1999). Patients receiving quercetin had a signiﬁ  cant 
improvement over the placebo group. Using prostaglandin 
E2 in expressed prostatic secretion as a surrogate marker 
of prostate inﬂ  ammation, it was later found that quecertin 
signiﬁ  cantly decreased inﬂ  ammation in the prostate (Shahed 
and Shoskes 2000, 2001). 
Neuromuscular and chronic pain therapy
Patients with CP/CPPS will often complain of pain and spasm 
of the pelvic ﬂ  oor muscles. Therapies aimed at relaxation of 
these muscle groups and proper use of pelvic ﬂ  oor muscle may 
therefore be expected to be beneﬁ  cial. Unfortunately, not very 
many large clinical trials have been published, data is available 
from small trials. For instance, biofeedback physical therapy 
and pelvic ﬂ  oor re-education lead to a signiﬁ  cant improvement 
of the NIH-CPSI score in men with CP/CPPS (Cornel et al 
2005). In another study, myofascial trigger point release and 
pelvic ﬂ  oor re-education also lead to a signiﬁ  cant improvement 
in NIH-CPSI score (Anderson et al 2005) and also improved 
sexual function in men with CP/CPPS (Anderson et al 2006). 
Also, a sham-controlled study of men with CP/CPPS found 
that electromagnetic therapy could signiﬁ  cantly improve the 
NIH-CPSI score of the patients, with the greatest improvement 
in the pain related symptoms (Rowe et al 2005). Amytriptyline 
(Holroyd et al 2001) and gabapentin (Covington 1998) can 
both be useful for the management of chronic pain and chronic 
muscle pain conditions and we have used them with some 
success in the management of patients with CP/CPPS.
Prostatic stone therapy
The role of prostatic calciﬁ  cation is unclear in the etiology 
of CP/CPPS. Indeed, many asymptomatic older men have 
stones detected during transrectal ultrasound. However, large, 
central calciﬁ  cations are often associated with symptoms in 
younger men (Geramoutsos et al 2004). Nanobacteria have 
attracted attention of late with their possible implication 
in biomineralization (Kajander et al 2001).  With medical 
therapy against both nanobacteria and prostatic stones, it 
has been demonstrated that patients who had failed conven-
tional therapy for CP/CPPS saw their NIH-CPSI signiﬁ  cantly 
improve after such therapy (Shoskes, Thomas, and Gomez 
2005). Such an approach awaits validation through a placebo-
controlled study. 
Treatment approach
Given current data, we favor a complete examination of 
the patient followed by multimodal therapy. In a treatment 
naive patient, a 2–4 week course of antibiotics is reason-
able, but should not be continued if cultures are negative 
and there is no improvement in symptoms. If cultures are 
negative, we then use a combination of an alpha blocker 
(tamsulosin, alfusozin) and anti-inﬂ  ammatory phytotherapy 
(quercetin and bee pollen, for instance 1 capsule of Q-Urol 
(Farr Labs, Santa Monica CA) twice daily) for 6–12 weeks. 
If not successful, we use neuromuscular therapies such as 
pelvic muscle physical therapy, amytriptiline or gabapentin. 
In patients who don’t respond to conventional therapy and 
have prostatic stones on transrectal ultrasound, we use an 
anti-nanobacterial therapy such as Calciclear (Calgenex 
Corp, Tampa FL). In the minority of patients who do not 
improve with these therapies, referral to a pain management 
specialist is appropriate.
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